Cargando…
Safety and efficacy of bendamustine in the conditioning regimen for autologous stem cell transplantation in patients with relapsed/refractory lymphoma
BACKGROUND: Bendamustine is an attractive option for the management of both de novo and relapsed lymphomas. It is being increasingly used in the conditioning regimen for autologous stem cell transplantation (SCT) and can be an alternative to the traditionally-used carmustine. In this study, we aimed...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6614092/ https://www.ncbi.nlm.nih.gov/pubmed/31309088 http://dx.doi.org/10.5045/br.2019.54.2.108 |
_version_ | 1783433121082900480 |
---|---|
author | Shabbir-Moosajee, Munira Jehangir, Samad Sawani, Sobiya Muhammed, Tariq Ali, Natasha Sheikh, Usman Adil, Salman |
author_facet | Shabbir-Moosajee, Munira Jehangir, Samad Sawani, Sobiya Muhammed, Tariq Ali, Natasha Sheikh, Usman Adil, Salman |
author_sort | Shabbir-Moosajee, Munira |
collection | PubMed |
description | BACKGROUND: Bendamustine is an attractive option for the management of both de novo and relapsed lymphomas. It is being increasingly used in the conditioning regimen for autologous stem cell transplantation (SCT) and can be an alternative to the traditionally-used carmustine. In this study, we aimed to determine the safety and efficacy of bendamustine in the conditioning regimen for autologous SCT in refractory/relapsed lymphomas. METHODS: We designed a descriptive study to evaluate bendamustine in combination with etoposide, cytarabine, and melphalan (BeEAM) in the conditioning regimen for autologous SCT. RESULTS: Fourteen patients (median age, 28 yr) with Hodgkin's lymphoma (HL) (N=8), non-Hodgkin's lymphomas (NHL) (N=5), or peripheral T-cell lymphoma, not otherwise specified (PTCL NOS) (N=1) were included in the study. A median number of 5.95×10(6) CD34+ cells/kg were transfused. Median times to absolute neutrophil count and platelet engraftment were 17 days and 24 days, respectively. The 100-day transplantation mortality rate was 28% (4 patients). Eight patients (57.14%) had GII-III acute kidney injury, four patients (28.5%) had GIII-IV hyperbilirubinemia, and twelve patients (85%) had GII-III diarrhea. After 3 months, 37% (5 patients) and 21.4% (3 patients) demonstrated complete response and partial response, respectively. The median follow-up was 5.5 months (15 days–19 mo). At the final follow-up, 7 patients (50%) were alive and in CR. CONCLUSION: Our study showed that bendamustine is a potentially toxic agent in the conditioning regimen for autologous SCT, resulting in significant liver, kidney, and gastrointestinal toxicity. Further studies are required to assess its safety and efficacy at reduced doses. |
format | Online Article Text |
id | pubmed-6614092 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis |
record_format | MEDLINE/PubMed |
spelling | pubmed-66140922019-07-15 Safety and efficacy of bendamustine in the conditioning regimen for autologous stem cell transplantation in patients with relapsed/refractory lymphoma Shabbir-Moosajee, Munira Jehangir, Samad Sawani, Sobiya Muhammed, Tariq Ali, Natasha Sheikh, Usman Adil, Salman Blood Res Original Article BACKGROUND: Bendamustine is an attractive option for the management of both de novo and relapsed lymphomas. It is being increasingly used in the conditioning regimen for autologous stem cell transplantation (SCT) and can be an alternative to the traditionally-used carmustine. In this study, we aimed to determine the safety and efficacy of bendamustine in the conditioning regimen for autologous SCT in refractory/relapsed lymphomas. METHODS: We designed a descriptive study to evaluate bendamustine in combination with etoposide, cytarabine, and melphalan (BeEAM) in the conditioning regimen for autologous SCT. RESULTS: Fourteen patients (median age, 28 yr) with Hodgkin's lymphoma (HL) (N=8), non-Hodgkin's lymphomas (NHL) (N=5), or peripheral T-cell lymphoma, not otherwise specified (PTCL NOS) (N=1) were included in the study. A median number of 5.95×10(6) CD34+ cells/kg were transfused. Median times to absolute neutrophil count and platelet engraftment were 17 days and 24 days, respectively. The 100-day transplantation mortality rate was 28% (4 patients). Eight patients (57.14%) had GII-III acute kidney injury, four patients (28.5%) had GIII-IV hyperbilirubinemia, and twelve patients (85%) had GII-III diarrhea. After 3 months, 37% (5 patients) and 21.4% (3 patients) demonstrated complete response and partial response, respectively. The median follow-up was 5.5 months (15 days–19 mo). At the final follow-up, 7 patients (50%) were alive and in CR. CONCLUSION: Our study showed that bendamustine is a potentially toxic agent in the conditioning regimen for autologous SCT, resulting in significant liver, kidney, and gastrointestinal toxicity. Further studies are required to assess its safety and efficacy at reduced doses. Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2019-06 2019-06-25 /pmc/articles/PMC6614092/ /pubmed/31309088 http://dx.doi.org/10.5045/br.2019.54.2.108 Text en © 2019 Korean Society of Hematology http://creativecommons.org/licenses/by-nc/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Shabbir-Moosajee, Munira Jehangir, Samad Sawani, Sobiya Muhammed, Tariq Ali, Natasha Sheikh, Usman Adil, Salman Safety and efficacy of bendamustine in the conditioning regimen for autologous stem cell transplantation in patients with relapsed/refractory lymphoma |
title | Safety and efficacy of bendamustine in the conditioning regimen for autologous stem cell transplantation in patients with relapsed/refractory lymphoma |
title_full | Safety and efficacy of bendamustine in the conditioning regimen for autologous stem cell transplantation in patients with relapsed/refractory lymphoma |
title_fullStr | Safety and efficacy of bendamustine in the conditioning regimen for autologous stem cell transplantation in patients with relapsed/refractory lymphoma |
title_full_unstemmed | Safety and efficacy of bendamustine in the conditioning regimen for autologous stem cell transplantation in patients with relapsed/refractory lymphoma |
title_short | Safety and efficacy of bendamustine in the conditioning regimen for autologous stem cell transplantation in patients with relapsed/refractory lymphoma |
title_sort | safety and efficacy of bendamustine in the conditioning regimen for autologous stem cell transplantation in patients with relapsed/refractory lymphoma |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6614092/ https://www.ncbi.nlm.nih.gov/pubmed/31309088 http://dx.doi.org/10.5045/br.2019.54.2.108 |
work_keys_str_mv | AT shabbirmoosajeemunira safetyandefficacyofbendamustineintheconditioningregimenforautologousstemcelltransplantationinpatientswithrelapsedrefractorylymphoma AT jehangirsamad safetyandefficacyofbendamustineintheconditioningregimenforautologousstemcelltransplantationinpatientswithrelapsedrefractorylymphoma AT sawanisobiya safetyandefficacyofbendamustineintheconditioningregimenforautologousstemcelltransplantationinpatientswithrelapsedrefractorylymphoma AT muhammedtariq safetyandefficacyofbendamustineintheconditioningregimenforautologousstemcelltransplantationinpatientswithrelapsedrefractorylymphoma AT alinatasha safetyandefficacyofbendamustineintheconditioningregimenforautologousstemcelltransplantationinpatientswithrelapsedrefractorylymphoma AT sheikhusman safetyandefficacyofbendamustineintheconditioningregimenforautologousstemcelltransplantationinpatientswithrelapsedrefractorylymphoma AT adilsalman safetyandefficacyofbendamustineintheconditioningregimenforautologousstemcelltransplantationinpatientswithrelapsedrefractorylymphoma |